Annals of Oncology Advance Access published online on June 23, 2006
Annals of Oncology, doi:10.1093/annonc/mdl145
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Research Unit in Medical Senology, Milan, Italy
* To whom correspondence should be addressed. Background: There is limited knowledge about prognosis, and treatment effects in young women with node-negative disease. Patients and Methods: We evaluated biological features, treatment recommendations and prognosis for 841 premenopausal patients with pT1-3, pN0 and M0, operated from 1997 to 2001. Results: Patients below 35 years (101, 12%) were more likely to have tumors > 2 cm (35.6% versus 24.2%, P = 0.002), grade 3 (48.5% versus 31.9%, P = 0.009) and with elevated Ki-67 expression (62.4% versus 50.7%, P = 0.002). At the multivariate analysis a statistically significant difference in disease-free survival (DFS, HR 4.44; 95% CI 2.53 to 7.78, P < 0.0001), risk of distant metastases (DDFS) (HR 3.23; 95% CI 1.32 to 7.94, P = 0.011) and overall survival (OS) (HR 2.89; 95% CI 1.06 to 7.87, P = 0.038) was observed for younger versus older patients and in the subgroup with endocrine responsive tumors (DFS, HR 5.17, 95% CI 2.72-9.83, P = < 0.0001; DDFS, 3.76, 95% CI 1.33-10.6, P = 0.013; OS, 4.71, 95% CI 1.09-20.4, P = 0.039 ). Conclusions: Compared with less young, very young patients with endocrine responsive and node-negative breast cancer have a worse prognosis. Tailored treatments should be explored in this cohort of patients.
Received March 11, 2006
Revised May 6, 2006
Accepted May 16, 2006
original article
Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease
M. Colleoni 1 *,
N. Rotmensz 2,
G. Peruzzotti 1,
P. Maisonneuve 2,
L. Orlando 1,
R. Ghisini 1,
G. Viale 3,
G. Pruneri 4,
P. Veronesi 5,
A. Luini 6,
M. Intra 6,
A. Cardillo 1,
R. Torrisi 1,
A. Rocca 1,
and
A. Goldhirsch 7
2 Division of Epidemiology and Biostatistics, Milan, Italy
3 Division of Pathology, Milan, Italy; University of Milan School of Medicine, Milan, Italy
4 Division of Pathology, Milan, Italy
5 University of Milan School of Medicine, Milan, Italy; Division of Senology, Milan, Italy
6 Division of Senology, Milan, Italy
7 Department of Medicine, European Institute of Oncology, Milan, Italy
M. Colleoni, E-mail: marco.colleoni{at}ieo.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. J. Burstein, I. Souter, H. A. D'Alessandro, and D. C. Sgroi Case 25-2009 -- A 36-Year-Old Woman with Hormone-Receptor-Positive Breast Cancer N. Engl. J. Med., August 13, 2009; 361(7): 699 - 707. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Lin, J.-Y. Liau, Y.-S. Lu, C.-S. Huang, W.-C. Lee, K.-T. Kuo, Y.-C. Shen, S.-H. Kuo, C. Lan, J. M. Liu, et al. Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1807 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2207 - 2209. [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Ahn, B. H. Son, S. W. Kim, S. I. Kim, J. Jeong, S.-S. Ko, and W. Han Poor Outcome of Hormone Receptor-Positive Breast Cancer at Very Young Age Is Due to Tamoxifen Resistance: Nationwide Survival Data in Korea--A Report From the Korean Breast Cancer Society J. Clin. Oncol., June 10, 2007; 25(17): 2360 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Aebi and M Castiglione The enigma of young age. Ann. Onc., October 1, 2006; 17(10): 1475 - 1477. [Full Text] [PDF]
|
|